Do analysts rate STRR or MBAI?

Star Equity currently has a consensus price target of $28.00, indicating a potential upside of 153.62%. Given Star Equity's stronger consensus rating and higher possible upside, equities research analysts plainly believe Star Equity is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Star Equity 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer STRR or MBAI?

In the previous week, Star Equity had 5 more articles in the media than Check-Cap. MarketBeat recorded 9 mentions for Star Equity and 4 mentions for Check-Cap. Star Equity's average media sentiment score of 1.39 beat Check-Cap's score of 0.91 indicating that Star Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Star Equity 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Check-Cap 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MBAI or NTRB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is MBAI or NTRB more profitable?

Check-Cap has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Check-Cap's return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Nutriband -448.25% -106.75% -92.74%

Do analysts prefer TELA or MBAI?

TELA Bio presently has a consensus target price of $2.20, suggesting a potential upside of 155.81%. Given TELA Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe TELA Bio is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TELA or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% Check-Cap N/A N/A N/A

Do analysts prefer MBAI or NEPH?

Nephros has a consensus price target of $6.00, indicating a potential upside of 79.64%. Given Nephros' stronger consensus rating and higher possible upside, analysts clearly believe Nephros is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nephros 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is MBAI or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Check-Cap's net margin of 0.00%. Nephros' return on equity of 7.66% beat Check-Cap's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Nephros 4.06% 7.66% 5.86%

Do analysts rate MBAI or PSTV?

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,025.75%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Check-Cap (MBAI) Competitors

$1.39 +0.02 (+1.46%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 06/12/2026 07:31 PM Eastern

Compare

MBAI vs. STRR, NTRB, TELA, NEPH, and PSTV

Should you buy Check-Cap stock or one of its competitors? MarketBeat compares Check-Cap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Check-Cap include Star Equity (STRR), Nutriband (NTRB), TELA Bio (TELA), Nephros (NEPH), and Plus Therapeutics (PSTV). These companies are all part of the "medical equipment" industry.

How does Check-Cap compare to Star Equity?

Star Equity (NASDAQ:STRR) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Check-Cap has lower revenue, but higher earnings than Star Equity. Star Equity is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Star Equity	$172.16M	0.24	-$5.92M	-$2.63	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

Star Equity currently has a consensus price target of $28.00, indicating a potential upside of 153.62%. Given Star Equity's stronger consensus rating and higher possible upside, equities research analysts plainly believe Star Equity is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.8% of Star Equity shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 33.5% of Star Equity shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Check-Cap has a net margin of 0.00% compared to Star Equity's net margin of -4.18%. Check-Cap's return on equity of 0.00% beat Star Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Star Equity	-4.18%	-4.04%	-2.40%
Check-Cap	N/A	N/A	N/A

In the previous week, Star Equity had 5 more articles in the media than Check-Cap. MarketBeat recorded 9 mentions for Star Equity and 4 mentions for Check-Cap. Star Equity's average media sentiment score of 1.39 beat Check-Cap's score of 0.91 indicating that Star Equity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Star Equity	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Check-Cap	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Star Equity has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Summary

Star Equity beats Check-Cap on 10 of the 16 factors compared between the two stocks.

How does Check-Cap compare to Nutriband?

Check-Cap (NASDAQ:MBAI) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 52.2% of Nutriband shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Check-Cap has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, Check-Cap had 2 more articles in the media than Nutriband. MarketBeat recorded 4 mentions for Check-Cap and 2 mentions for Nutriband. Check-Cap's average media sentiment score of 0.91 beat Nutriband's score of 0.47 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Positive
Nutriband	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Check-Cap has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Check-Cap's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nutriband	-448.25%	-106.75%	-92.74%

Check-Cap has higher earnings, but lower revenue than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Nutriband	$2.04M	20.21	-$8.23M	-$2.60	N/A

Summary

Check-Cap beats Nutriband on 7 of the 13 factors compared between the two stocks.

How does Check-Cap compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
Check-Cap	N/A	N/A	N/A

94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TELA Bio has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.48	-$38.83M	-$0.79	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

In the previous week, Check-Cap had 3 more articles in the media than TELA Bio. MarketBeat recorded 4 mentions for Check-Cap and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 1.87 beat Check-Cap's score of 0.91 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
Check-Cap	Positive

TELA Bio presently has a consensus target price of $2.20, suggesting a potential upside of 155.81%. Given TELA Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe TELA Bio is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TELA Bio beats Check-Cap on 9 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Nephros?

Check-Cap (NASDAQ:MBAI) and Nephros (NASDAQ:NEPH) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Nephros has a net margin of 4.06% compared to Check-Cap's net margin of 0.00%. Nephros' return on equity of 7.66% beat Check-Cap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Nephros	4.06%	7.66%	5.86%

Nephros has a consensus price target of $6.00, indicating a potential upside of 79.64%. Given Nephros' stronger consensus rating and higher possible upside, analysts clearly believe Nephros is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Check-Cap had 3 more articles in the media than Nephros. MarketBeat recorded 4 mentions for Check-Cap and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat Check-Cap's score of 0.91 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Check-Cap	Positive
Nephros	Very Positive

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Check-Cap has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Check-Cap has higher earnings, but lower revenue than Nephros. Check-Cap is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Nephros	$18.79M	1.93	$1.19M	$0.07	47.71

Summary

Nephros beats Check-Cap on 13 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Plus Therapeutics?

Check-Cap (NASDAQ:MBAI) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Check-Cap has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Plus Therapeutics	$5.21M	6.62	-$22.39M	-$2.30	N/A

Check-Cap has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Check-Cap's return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,025.75%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Plus Therapeutics had 7 more articles in the media than Check-Cap. MarketBeat recorded 11 mentions for Plus Therapeutics and 4 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.91 beat Plus Therapeutics' score of -0.68 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Positive
Plus Therapeutics	Negative

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Plus Therapeutics beats Check-Cap on 9 of the 15 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	Check-Cap	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$9.99M	$2.81B	$4.94B	$12.02B
Dividend Yield	N/A	N/A	9.91%	5.61%
P/E Ratio	-0.50	12.29	22.22	24.43
Price / Sales	N/A	334.02	164.60	109.73
Price / Cash	2.41	8.13	42.20	55.64
Price / Book	2.96	5.47	27.17	6.79
Net Income	$4.14M	$7.39M	$118.48M	$337.66M
7 Day Performance	0.72%	-1.57%	0.64%	2.57%
1 Month Performance	-30.50%	-3.66%	-0.92%	2.04%
1 Year Performance	N/A	4.32%	13.98%	30.28%

Check-Cap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI Check-Cap	0.7528 of 5 stars	$1.39 +1.5%	N/A	N/A	$9.99M	N/A	N/A	80	Short Interest Decrease Gap Down
STRR Star Equity	4.4749 of 5 stars	$11.56 -0.3%	$28.00 +142.2%	+441.2%	$42.77M	$172.16M	N/A	1,200	Positive News Insider Trade
NTRB Nutriband	0.6188 of 5 stars	$3.49 -1.8%	N/A	-55.4%	$42.38M	$2.04M	N/A	10	Earnings Report
TELA TELA Bio	3.6933 of 5 stars	$0.88 -3.0%	$2.20 +149.2%	-53.5%	$40.20M	$80.28M	N/A	120
NEPH Nephros	2.5629 of 5 stars	$3.63 -4.5%	$6.00 +65.3%	-16.7%	$39.42M	$18.79M	51.86	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Check-Cap (MBAI) Competitors

MBAI vs. STRR, NTRB, TELA, NEPH, and PSTV

How does Check-Cap compare to Star Equity?

Summary

How does Check-Cap compare to Nutriband?

Summary

How does Check-Cap compare to TELA Bio?

Summary

How does Check-Cap compare to Nephros?

Summary

How does Check-Cap compare to Plus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Check-Cap (MBAI) Competitors

MBAI vs. STRR, NTRB, TELA, NEPH, and PSTV

How does Check-Cap compare to Star Equity?

Which has better valuation & earnings, STRR or MBAI?

Do analysts rate STRR or MBAI?

Do institutionals and insiders hold more shares of STRR or MBAI?

Is STRR or MBAI more profitable?

Does the media prefer STRR or MBAI?

Which has more risk and volatility, STRR or MBAI?

Summary

How does Check-Cap compare to Nutriband?

Do insiders & institutionals have more ownership in MBAI or NTRB?

Which has more volatility & risk, MBAI or NTRB?

Does the media favor MBAI or NTRB?

Do analysts rate MBAI or NTRB?

Is MBAI or NTRB more profitable?

Which has preferable earnings & valuation, MBAI or NTRB?

Summary

How does Check-Cap compare to TELA Bio?

Is TELA or MBAI more profitable?

Do insiders and institutionals have more ownership in TELA or MBAI?

Which has more volatility & risk, TELA or MBAI?

Which has better valuation and earnings, TELA or MBAI?

Does the media prefer TELA or MBAI?

Do analysts prefer TELA or MBAI?

Summary

How does Check-Cap compare to Nephros?

Is MBAI or NEPH more profitable?

Do analysts prefer MBAI or NEPH?

Does the media favor MBAI or NEPH?

Do insiders and institutionals hold more shares of MBAI or NEPH?

Which has more risk & volatility, MBAI or NEPH?

Which has stronger earnings & valuation, MBAI or NEPH?

Summary

How does Check-Cap compare to Plus Therapeutics?

Which has more risk & volatility, MBAI or PSTV?

Which has stronger valuation and earnings, MBAI or PSTV?

Is MBAI or PSTV more profitable?

Do analysts rate MBAI or PSTV?

Does the media prefer MBAI or PSTV?

Do institutionals & insiders believe in MBAI or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools